Tevogen Bio Holdings에 대한 매도 수량은 투자자에게 Tevogen Bio Holdings의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Tevogen Bio Holdings (NASDAQ:TVGN) 주식, 공매도 수량 보고

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Exclusives

Trading Ideas

AAPL

AMZN

DRUG

GLMD

GNPX

INTC

LUNR

MSFT

MSTR

NVDA

OKLO

PLTR

SMCI

SOFI

TSLA

TVGN

WHLR

WULF

매 거래일마다 수백 개의 헤드라인과 보도자료가 벤징가 프로에 올라와, 트레이더들이 전체 시장과 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 10월에 벤징가 프로에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 실적은 11월 1일 기준이며 배당금은 포함되지 않았다.

독점: 벤징가 프로에서 10월 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, DJT 순위는?

Tevogen Bio Holdings Inc

News

Contracts

KTOS

Naval Air Systems Command Awards Kratos Additional $59.3M For BQM-177A Subsonic Aerial Target Systems

Management

Masco Corporation CEO Keith Allman To Retire, Jonathon Nudi To Be Appointed PREsident And CEO Effective Jul. 7

B of A Securities analyst Vivek Arya maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and lowers the price target from $150 to $120.

Price Target

Analyst Ratings

MRVL

B of A Securities Maintains Buy on Marvell Tech, Lowers Price Target to $120

Macro Economic Events

Global

Economics

ECB Cuts Deposit Facility Rate From 2.75% To 2.5%, Cuts Refi Rate From 2.9% To 2.65%

Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) shares are trading higher in the <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">premarket session on Thursday</a>.
The company reported fourth-quarter adjusted earnings per share of $4.13, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44161791/burlington-stores-inc-reports-fourth-quarter-and-full-year-2024-earnings" rel="noreferrer noopener">beating the street view of $3.76.</a>
Quarterly sales of $3.28 billion (+5% year over year) outpaced the analyst consensus estimate of $3.23 billion. Comparable store sales growth for the quarter was 6%, versus&nbsp;guidance&nbsp;of&nbsp;0%&nbsp;to&nbsp;2%.
&#8220;Taking 2024 as a whole, total sales increased 11%, comparable store sales increased 4%, and Adjusted EBIT Margin increased 100 basis points,&#8221; said Michael O&#8217;Sullivan, CEO.&nbsp;
The quarterly gross profit was $1.404 billion, up from $1.333 billion in the year-ago period. Gross margin expanded by 30 basis points to 42.9%, freight improved by 20 basis points, and merchandise margin increased by 10 basis points.
Adjusted EBITDA&nbsp;was $456 million in the quarter under review, higher than $412 million in the year-ago period.
Also Read:<a target="_blank" href="https://www.benzinga.com/news/large-cap/25/03/44161401/rio-tintos-1-8-billion-iron-ore-expansion-ramps-up-in-australia-details" rel="noreferrer noopener"> Rio Tinto&#8217;s $1.8 Billion Iron Ore Expansion Ramps Up In Australia: Details</a>
&#8220;We opened 101 net new stores in 2024 and relocated 31 of our older oversized locations,&#8221; the CEO added.
The company ended the fourth quarter with $1.822 billion in liquidity, comprised of $995 million in unrestricted cash.
Outlook: &#8220;The outlook for 2025 is very uncertain and we will plan and manage our business accordingly,&#8221; the CEO said.
The company expects total sales to increase by 6% &#8211; 8%, on top of the 11% increase the prior year. The company sees adjusted EPS of $8.70 &#8211; $9.30 (estimate: $9.43).
Burlington expects first-quarter total sales to increase 5% &#8211; 7%, comparable store sales are expected to be flattish. The company sees adjusted EPS of $1.30 &#8211; $1.45 (estimate: $1.68).
Price Action: BURL shares are trading higher by 12.5% to $266.50 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/forex/25/03/44161314/us-stocks-likely-to-open-lower-after-wednesdays-blip-be-patient-but-be-ready-to-act-says-analyst-as-market-uncertainties-can-create-opportunities" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Lower After Wednesday&#8217;s Blip: &#8216;Be Patient, But Be Ready To Act,&#8217; Says Analyst As Market Uncertainties Can Create &#8216;Opportunities&#8217;</a></li>
</ul>
Photo via Shutterstock.

Earnings

Equities

Guidance

Markets

Movers

General

BURL

Burlington Stock Jumps As Q4 Earnings Crush Estimates, But CEO Warns Of 'Uncertain' 2025 Outlook

WIIM

RYAAY

Ryanair shares are trading lower after Morgan Stanley downgraded its rating on the stock from overweight to equal weight.

ADTX

Aditxt'ss Adimune Subsidiary To Ship Drug Substances For Final Drug Product Formulation Of ADI-100 Ahead Of Planned Trials For Type 1 Diabetes And Psoriasis In Germany And Stiff Person Syndrome At Mayo Clinic

B of A Securities analyst Peter Galbo maintains Campbell`s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) with a Underperform and lowers the price target from $45 to $41.

B of A Securities Maintains Underperform on Campbell's, Lowers Price Target to $41

Small Cap Consumer Research analyst Eric Beder reiterates Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) with a Buy and maintains $5.5 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on Vera Bradley, Maintains $5.5 Price Target

VRME

VerifyMe shares are trading lower after the company reported worse-than-expected Q4 earnings and sales.

MRAM

Everspin Awarded $10.5M Contract For MRAM IP And Foundry Services For Purdue University's ME Commons In-Memory Compute Project

Baird analyst Shrenik Kothari maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Outperform and raises the price target from $240 to $250.

Baird Maintains Outperform on Zscaler, Raises Price Target to $250

Earnings Beats

Earnings Misses

VYNE

VYNE Therapeutics Q4 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $84.000K Miss $140.000K Estimate

Baird analyst Joe Vruwink maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $283 to $285.

VEEV

Baird Maintains Outperform on Veeva Systems, Raises Price Target to $285

ALLR

Allarity Therapeutics Announces ITs Phase 2 Trial Of Stenoparib In Combination With Temozolomide For Recurrent Small Cell Lung Cancer, Being Fully Funded By US Veterans Administration

Baird analyst William Power maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Outperform and lowers the price target from $390 to $300.

Baird Maintains Outperform on MongoDB, Lowers Price Target to $300

Curtiss-Wright Receives $18M Follow-On Order From US Marine Corps

No gainer in today's Pre-market session. 
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">217.58</td>
<td align="right">-3.99</td>
<td align="right">-1.81</td>
<td>19.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">49.70</td>
<td align="right">-0.51</td>
<td align="right">-1.02</td>
<td>255.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">209.31</td>
<td align="right">-2.10</td>
<td align="right">-1.00</td>
<td>364</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.95</td>
<td align="right">-0.54</td>
<td align="right">-0.70</td>
<td>5.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">148.93</td>
<td align="right">-0.75</td>
<td align="right">-0.51</td>
<td>4.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">43.20</td>
<td align="right">-0.22</td>
<td align="right">-0.51</td>
<td>1.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.06</td>
<td align="right">-0.38</td>
<td align="right">-0.47</td>
<td>1.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">85.34</td>
<td align="right">-0.36</td>
<td align="right">-0.43</td>
<td>13.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">87.84</td>
<td align="right">-0.20</td>
<td align="right">-0.23</td>
<td>326</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For March 6, 2025

Tesla shares are trading lower after Baird lowered its price target on the stock from $440 to $370.

Baird analyst Craig Kennison maintains Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) with a Outperform and lowers the price target from $110 to $100.

Baird Maintains Outperform on Thor Industries, Lowers Price Target to $100

Financing

Press Releases

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology's Potential as a Scalable Medical Countermeasure

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Health Care

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

TVGNW

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Tevogen Bio Holdings

매도 수량

Tevogen Bio Holdings (NASDAQ:TVGN) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌